Wolff D, Skourtopoulos M, Hörnschemeyer D, Wolff C, Körner M, Körfer R, Kleesiek K
Institut für Laboratoriums- und Transfusionsmedizin, Herz- und Diabeteszentrum Nordrhein-Westfalen, Universitätsklinik der Ruhr-Universität Bochum, Bad Oeynhausen, Germany.
Microbiol Res. 1996 Dec;151(4):343-9. doi: 10.1016/S0944-5013(96)80002-4.
PCR is a sensitive diagnostic tool for the detection of human cytomegalovirus (HCMV) DNA in the peripheral blood of immunosuppressed transplant recipients. However, its specificity as a prognostic marker for clinical disease is unclassified, because infections considered to be latent may be detected by this method. In order to diagnose active viral infections, we used reverse transcription-PCR (RT-PCR) to identify HCMV mRNA in blood. We developed a single-tube nested RT-PCR with preformed PCR mixtures embedded in a trehalose matrix. Blood samples of 48 heart transplant recipients were investigated for HCMV DNA. 8 patients detected to be HCMV DNA positive after transplantation were investigated in longitudinal monitoring for at least 6 months. HCMV mRNA was found in 5 patients who developed HCMV related symptoms during the period of RNA detection. There was no clear relation between the onset of DNA detection and the first demonstration of mRNA. In 2 patients HCMV DNA could be detected 74 and 81 days before the appearance of mRNA, suggesting long persistence until active infection is started. In 3 patients HCMV mRNA disappeared during or immediately after the end of ganciclovir therapy. In contrast, HCMV DNA was detectable continuously for prolonged periods after therapy, indicating that the persistence of HCMV DNA is not influenced by ganciclovir treatment. In summary, HCMV DNA detection seems to be a reliable early marker for the differentiation of persistent and active HCMV infections in immunosuppressed patients. Our data show that viral mRNA detection is probably a better predictor of the effectiveness of antiviral therapy than viral DNA detection.
聚合酶链反应(PCR)是一种用于检测免疫抑制移植受者外周血中人类巨细胞病毒(HCMV)DNA的灵敏诊断工具。然而,其作为临床疾病预后标志物的特异性尚未明确,因为该方法可能检测到被认为是潜伏性的感染。为了诊断活动性病毒感染,我们使用逆转录PCR(RT-PCR)来鉴定血液中的HCMV mRNA。我们开发了一种单管巢式RT-PCR,其中预形成的PCR混合物包埋在海藻糖基质中。对48名心脏移植受者的血样进行了HCMV DNA检测。对移植后检测为HCMV DNA阳性的8名患者进行了至少6个月的纵向监测。在RNA检测期间出现HCMV相关症状的5名患者中发现了HCMV mRNA。DNA检测的开始与mRNA的首次出现之间没有明确的关系。在2名患者中,在mRNA出现前74天和81天可检测到HCMV DNA,这表明在活动性感染开始前病毒长期持续存在。在3名患者中,HCMV mRNA在更昔洛韦治疗期间或结束后立即消失。相比之下,治疗后HCMV DNA可长时间持续检测到,这表明HCMV DNA的持续存在不受更昔洛韦治疗的影响。总之,HCMV DNA检测似乎是区分免疫抑制患者中持续性和活动性HCMV感染的可靠早期标志物。我们的数据表明,病毒mRNA检测可能比病毒DNA检测更能预测抗病毒治疗的效果。